OCULAR THERAPEUTIX, INC Interest Expense Nonoperating
OCULAR THERAPEUTIX, INC (OCUL) reported Interest Expense Nonoperating of $2.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC interest expense nonoperating for the quarter ending 2026-06-30 was $2.79M, a 7.43% decline year-over-year.
- OCULAR THERAPEUTIX, INC interest expense nonoperating for the quarter ending 2026-03-31 was $2.78M, a 6.94% decline year-over-year.
- OCULAR THERAPEUTIX, INC interest expense nonoperating for the quarter ending 2025-12-31 was $2.83M, a 8.82% decline year-over-year.
- OCULAR THERAPEUTIX, INC interest expense nonoperating for the quarter ending 2025-09-30 was $3.00M, a 6.89% decline year-over-year.
- OCULAR THERAPEUTIX, INC interest expense nonoperating for fiscal 2025 was $11.84M, a 12.83% decline from fiscal 2024.
- OCULAR THERAPEUTIX, INC interest expense nonoperating for fiscal 2024 was $13.58M, a 19.75% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC interest expense nonoperating for fiscal 2023 was $11.34M, a 61.46% increase from fiscal 2022.
- OCULAR THERAPEUTIX, INC interest expense nonoperating for fiscal 2022 was $7.02M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.79M 10-Q · filed 2026-08-03 | $5.57M 10-Q · filed 2026-08-03 | $8.40M derived: sum of 3 quarters · filed 2026-08-03 | $11.40M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $2.78M 10-Q · filed 2026-05-05 | $5.61M derived: sum of 2 quarters · filed 2026-05-05 | $8.61M derived: sum of 3 quarters · filed 2026-05-05 | $11.63M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $5.83M derived: sum of 2 quarters · filed 2026-02-05 | $8.85M derived: sum of 3 quarters · filed 2026-08-03 | $11.84M 10-K · filed 2026-02-05 |
| 2025-09-30 | $3.00M 10-Q · filed 2025-11-04 | $6.02M derived: sum of 2 quarters · filed 2026-08-03 | $9.00M 10-Q · filed 2025-11-04 | $12.11M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $3.02M 10-Q · filed 2026-08-03 | $6.00M 10-Q · filed 2026-08-03 | $9.11M derived: sum of 3 quarters · filed 2026-08-03 | $12.33M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $2.98M 10-Q · filed 2026-05-05 | $6.09M derived: sum of 2 quarters · filed 2026-05-05 | $9.31M derived: sum of 3 quarters · filed 2026-05-05 | $12.51M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $6.33M derived: sum of 2 quarters · filed 2026-02-05 | $9.53M derived: sum of 3 quarters · filed 2026-02-05 | $13.58M 10-K · filed 2026-02-05 |
| 2024-09-30 | $3.22M 10-Q · filed 2025-11-04 | $6.42M derived: sum of 2 quarters · filed 2025-11-04 | $10.47M 10-Q · filed 2025-11-04 | $14.62M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-06-30 | $3.20M 10-Q · filed 2025-08-05 | $7.25M 10-Q · filed 2025-08-05 | $11.40M derived: sum of 3 quarters · filed 2026-02-05 | $14.82M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-03-31 | $4.05M 10-Q · filed 2025-05-05 | $8.20M derived: sum of 2 quarters · filed 2026-02-05 | $11.63M derived: sum of 3 quarters · filed 2026-02-05 | $13.62M derived: sum of 4 quarters · filed 2026-02-05 |
| 2023-12-31 | $4.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $7.58M derived: sum of 2 quarters · filed 2026-02-05 | $9.57M derived: sum of 3 quarters · filed 2026-02-05 | $11.34M 10-K · filed 2026-02-05 |
| 2023-09-30 | $3.43M 10-Q · filed 2024-11-14 | $5.42M derived: sum of 2 quarters · filed 2024-11-14 | $7.19M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $1.99M 10-Q · filed 2024-08-07 | $3.76M 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | $7.02M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |